Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy

• 作者: Jian Xue Hongbo Ni Fan Wang Ke Xu Meng Niu
• 来源期刊: 介入医学杂志（英文）
• 年，卷（期）: 2021,（3）
• 所属期刊栏目: Review
• 页码范围: 105-113
• 页数: 9页
• 语种: 中文

摘要

Locoregional therapies (LRTs) of hepatocellular carcinoma (HCC) represented by ablation and TACE has become the main means for the clinical treatment of unresectable HCC.Among these,TACE is used throughout the stageⅠb to Ⅲb of HCC treatment.In recent years,immunotherapy led by immune checkpoint inhibitors has become a hot direction in clinical research.At the same time,targeted drugs such as Sorafenib and Apatinib have played an important role in the treatment and complementary therapy of advanced HCC,and their clinical application has been quite mature.HCC is the sixth most common malignant tumor in the world.When it comes to its treatment,different therapies have different indications,and their individual efficacies are not satisfactory,which makes the exploration of the use of combination therapy in HCC treatment become a new trend.In this paper,the status of the three therapies and the progress of their combined application are briefly reviewed.